Piper Sandler Maintains Overweight on LENZ Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro maintains an Overweight rating on LENZ Therapeutics (NASDAQ:LENZ) with a $36 price target.
August 15, 2024 | 5:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Joseph Catanzaro maintains an Overweight rating on LENZ Therapeutics with a $36 price target.
The reaffirmation of an Overweight rating and a $36 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100